




Instance: composition-en-a7d93b3af6f699fe631629c6d79268c4
InstanceOf: CompositionUvEpi
Title: "Composition for xermelo Package Leaflet"
Description:  "Composition for xermelo Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpa7d93b3af6f699fe631629c6d79268c4)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - xermelo"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Xermelo is and what it is used for  </li>
<li>What you need to know before you take Xermelo  </li>
<li>How to take Xermelo  </li>
<li>Possible side effects  </li>
<li>How to store Xermelo  </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What xermelo is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What xermelo is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Xermelo is 
This medicine contains the active substance telotristat ethyl.  </p>
<p>What Xermelo is used for 
This medicine is used in adults with a condition called  carcinoid syndrome . This is when a tumour, 
called a  neuroendocrine tumour , releases a substance called serotonin into your bloodstream.  </p>
<p>Your doctor will prescribe this medicine if your diarrhoea is not well controlled with injections of 
other medicines called  somatostatin analogues  (lanreotide or octreotide). You should keep having 
injections of these other medicines when taking Xermelo. </p>
<p>How Xermelo works 
When the tumour releases too much serotonin into your bloodstream you can get diarrhoea.<br />
This medicine works by reducing the amount of serotonin made by the tumour. It will reduce your 
diarrhoea.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take xermelo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take xermelo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Xermelo 
- if you are allergic to telotristat or any of the other ingredients of this medicine (listed in 
section 6). </p>
<p>Warnings and precautions<br />
Talk to your doctor or pharmacist before taking Xermelo: 
  if you have liver problems. This is because this medicine is not recommended for use in patients 
with severe liver problems. Your doctor may decide to decrease your daily dose of Xermelo in 
cases where your liver problems are considered mild or moderate. Your doctor will also monitor 
your liver. 
  if you have end-stage kidney disease or are on dialysis. This is because this medicine has not been 
tested in patients with end-stage kidney disease, requiring dialysis.  </p>
<p>Look out for side effects 
Tell your doctor straight away if you notice any of the following signs and symptoms that suggest that 
your liver may not be working properly: 
  feeling or being sick (unexplained nausea or vomiting), abnormally dark urine, yellow skin or eyes, 
pain in the upper right belly.<br />
Your doctor will do blood tests to check your liver and will decide whether you should keep taking 
this medicine. </p>
<p>Talk to your doctor or pharmacist: 
  if you feel down, depressed, or if you feel you have no interest or take any pleasure in doing your 
normal activities, whilst taking this medicine, as depression, depressed mood and decreased interest 
have been reported in patients treated with telotristat. 
  if you have signs of constipation, as telotristat reduces the number of your bowel movements. </p>
<p>Tests 
  Your doctor may carry out blood tests before you start taking this medicine and while you are 
taking it. This is to check that your liver is working normally. </p>
<p>Children and adolescents 
This medicine is not recommended in patients below 18 years old. This is because the medicine has 
not been studied in this age group. </p>
<p>Other medicines and Xermelo 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. This is because Xermelo can affect the way some other medicines work, or other medicines 
can affect the way Xermelo works. This could mean that your doctor needs to change the dose(s) that 
you take. You should tell your doctor about every medicine. This includes:<br />
  medicines for diarrhoea. Xermelo and these medicines reduce the number of your bowel 
movements and taken together, they can cause severe constipation. Your doctor may need to 
change the dose of your medicines.<br />
  medicines used to treat epilepsy, such as valproic acid. 
  medicines used to treat your neuroendocrine tumour, such as sunitinib or everolimus. 
  medicines to treat depression, such as bupropion or sertraline. 
  medicines used to avoid transplant rejection, such as cyclosporine. 
  medicines used to lower cholesterol levels, such as simvastatin. 
  oral contraceptives, such as ethinyloestradiol.<br />
  medicines used to treat high blood pressure, such as amlodipine. 
  medicines used to treat some types of cancers, such as irinotecan, capecitabine and flutamide. 
  medicines used to reduce the chance of a blood clot forming, such as prasugrel. 
  octreotide. If you need treatment with octreotide subcutaneous injections, you should have your 
injection at least 30 minutes after taking Xermelo. </p>
<p>Pregnancy and breast-feeding<br />
If you are pregnant or breast-feeding, think you might be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine.<br />
You should not take this medicine if you are pregnant or might become pregnant. It is not known how 
telotristat may affect the baby.<br />
Women should use effective methods of contraception while taking this medicine. 
You should not breast-feed if you are taking Xermelo, as this medicine may be passed on to your baby 
and may harm your baby. </p>
<p>Driving and using machines 
Xermelo may have a small effect on your ability to drive or use any tools or machines. If you feel 
tired, you should wait until you feel better before driving or using any tools or machines. </p>
<p>Xermelo contains lactose 
Xermelo contains lactose (a type of sugar). If you have been told by your doctor that you have an 
intolerance to some sugars, contact your doctor before taking this medicine. </p>
<p>Xermelo contains sodium 
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 
 sodium-free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take xermelo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take xermelo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure.  </p>
<p>How much to take 
The recommended dose is one tablet (250 mg) three times a day. The maximum dose of Xermelo is 
750 mg in 24 hours. 
Your doctor will decide for how long you should take Xermelo. 
If you have liver problems, your doctor may decide to reduce your daily dose of Xermelo. </p>
<p>Taking this medicine 
  Always take this medicine with a meal or some food.<br />
  You should keep having injections of somatostatin analogues (lanreotide or octreotide) when taking 
Xermelo. </p>
<p>If you take more Xermelo than you should 
You may feel sick or be sick, have diarrhoea or stomach ache. Talk to a doctor. Take the medicine 
pack with you.  </p>
<p>If you forget to take Xermelo 
If you forget to take a dose, take your next dose when it is due, skipping the missed dose. 
Do not take a double dose to make up for a forgotten dose. </p>
<p>If you stop taking Xermelo 
Do not stop taking Xermelo without talking with your doctor. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Tell your doctor immediately if you notice any of the following side effects: 
  feeling or being sick, abnormally dark urine, yellow skin or eyes, pain in the upper right belly. 
These may be signs that your liver is not working properly. This might also be shown by changes 
in your blood test results, such as an increase of liver enzymes: gamma-glutamyl transferase (very 
common, may affect more than 1 in 10 people), transaminases and blood alkaline phosphatase 
(common, may affect up to 1 in 10 people). </p>
<p>Other side effects 
Tell your doctor, pharmacist or nurse if you notice any of the following side effects: </p>
<p>Very common side effects (may affect more than 1 in 10 people):<br />
  Belly (abdominal) pain 
  Feeling tired or weak (fatigue) 
  Feeling sick (nausea) </p>
<p>Common side effects (may affect up to 1 in 10 people):<br />
  Wind 
  Fever 
  Headache<br />
  Constipation<br />
  Swollen stomach 
  Decreased appetite 
  Swelling (build-up of fluid in the body) 
  Depression, you may experience decreased self-esteem, lack of motivation, sadness or low mood </p>
<p>Uncommon side effects (may affect up to 1 in 100 people): 
  Impacted stools (bowel obstruction, faecaloma), you may experience, constipation, watery 
diarrhoea, pale skin (anaemia), nausea, vomiting, weight loss, back pain or stomach pains 
particularly after eating or a reduction in passing water (urination).<br />
Tell your doctor immediately if you experience any of the following side effects: 
  Breathing problems, rapid heartbeat, fever, incontinence (uncontrollable urination), confusion, 
dizziness or agitation.  </p>
<p>Tell your doctor, pharmacist or nurse if you notice any of the side effects listed above. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store xermelo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store xermelo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and the blister after EXP. 
The expiry date refers to the last day of that month. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>
<p>This medicine does not require any special storage conditions. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Xermelo contains<br />
- The active substance is telotristat ethyl. Each film-coated  tablet contains telotristat etiprate 
equivalent to 250 mg telotristat ethyl. 
- The other ingredients are:<br />
Tablet core: lactose (see section 2 under  Xermelo contains lactose ), hydroxypropylcellulose, 
croscarmellose sodium, magnesium stearate and colloidal anhydrous silica. 
Film-coating: poly(vinyl alcohol) (E1203), titanium dioxide (E171), macrogol 3350 (E1521) and talc 
(E553b).  </p>
<p>What Xermelo looks like and contents of the pack 
The tablets are white to off-white, film-coated and oval shaped. Each tablet is approximately 17 mm 
long by 7.5 mm wide with  T-E  debossed on one side and  250  debossed on the other. The tablets are 
packaged in a PVC/PCTFE/PVC/Al blister. The blisters are packaged in a carton. </p>
<p>Cartons of 90 and 180 tablets. Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder<br />
SERB SAS 
40 Avenue George V 
75008 Paris<br />
France </p>
<p>Manufacturer 
Tjoapack Netherlands B.V. 
Nieuwe Donk 9 
4879 AC Etten-Leur<br />
Netherlands </p>
<p>This leaflet was last revised in  </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site:  </p>         </div>"""      



Instance: composition-da-a7d93b3af6f699fe631629c6d79268c4
InstanceOf: CompositionUvEpi
Title: "Composition for xermelo Package Leaflet"
Description:  "Composition for xermelo Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpa7d93b3af6f699fe631629c6d79268c4)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - xermelo"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse<br />
2. Det skal du vide, før du begynder at tage bruge Xermelo 
3. Sådan skal du tage Xermelo 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What xermelo is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What xermelo is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Hvad Xermelo er 
Xermelo indeholder det aktive stof telotristatethyl. </p>
<p>Hvad Xermelo anvendes til 
Xermelo anvendes hos voksne til en tilstand, der kaldes "karcinoid syndrom". Det er når en tumor, 
kaldet en "neuroendokrin tumor", frigiver et stof, som hedder serotonin, ud i blodbanen. </p>
<p>Din læge vil give dig dette lægemiddel, hvis din diarré ikke er velkontrolleret med injektioner af anden 
medicin, som kaldes "somatostatinanaloger" (lanreotid eller octreotid). Du skal fortsat have 
injektioner med disse andre lægemidler, når du tager Xermelo.  </p>
<p>Sådan virker Xermelo 
Når tumoren frigiver for meget serotonin ud i blodbanen, kan du få diarré. 
Denne medicin virker ved at nedsætte den mængde af serotonin, som tumoren producerer. Det vil 
reducere din diarré. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take xermelo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take xermelo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Xermelo 
- Hvis du er allergisk over for telotristat eller et af de øvrige indholdsstoffer i dette lægemiddel 
(angivet i punkt 6). </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før du tager Xermelo: </p>
<ul>
<li>
<p>hvis du har leverproblemer. Dette er fordi, denne medicin ikke anbefales til patienter med 
alvorlige leverproblemer. Din læge kan beslutte at nedsætte din daglige Xermelo dosis, hvis 
dine leverproblemer anses for lette eller moderate. Din læge vil også overvåge, om din lever 
påvirkes. </p>
</li>
<li>
<p>Tal med din læge, hvis du har terminal nyresygdom eller er i dialyse. Dette skyldes, at dette 
lægemiddel ikke er blevet undersøgt hos patienter med dialysekrævende terminal nyresygdom. </p>
</li>
</ul>
<p>Vær opmærksom på bivirkninger 
Fortæl det straks til lægen, hvis du bemærker et af følgende tegn eller symptomer på, at din lever 
måske ikke fungerer rigtigt: </p>
<ul>
<li>uforklarlig kvalme eller opkast, unormalt mørk urin, gul hud eller gule øjne, smerter øverst til 
højre i maven. 
Din læge vil tage blodprøver for at tjekke leveren og beslutte, om du fortsat skal tage denne medicin. </li>
</ul>
<p>Tal med lægen eller apotekspersonalet: </p>
<ul>
<li>
<p>hvis du føler dig nedtrykt, deprimeret, eller hvis du føler dig uinteresseret i eller uden glæde i at 
udføre dine normale aktiviteter, når du tager denne medicin, da depression, nedtrykthed og 
nedsat interesse er blevet rapporteret hos patienter behandlet med telotristat. </p>
</li>
<li>
<p>hvis du har symptomer på forstoppelse, da telotristat nedsætter tarmbevægelserne (antal 
afføringer). </p>
</li>
</ul>
<p>Prøver </p>
<ul>
<li>Lægen kan tage blodprøver før du begynder at tage dette lægemiddel og mens du tager det. Det 
er for at undersøge, om at din lever fungerer normalt. </li>
</ul>
<p>Børn og unge 
Denne medicin anbefales ikke til patienter under 18 år. Dette skyldes, at medicinen ikke er blevet 
undersøgt i denne aldersgruppe. </p>
<p>Brug af anden medicin sammen med Xermelo 
Fortæl det altid til lægen eller apotekspersonalet, hvis du tager anden medicin eller for nylig har taget 
anden medicin eller planlægger at tage anden medicin. Det skyldes, at Xermelo kan påvirke den måde 
anden medicin virker på, eller anden medicin kan påvirke den måde, Xermelo virker på. Dette kan 
betyde, at din læge skal ændre den dosis/de doser, som du tager. Du skal fortælle din læge om al 
medicin, som du tager. Dette inkluderer: </p>
<ul>
<li>
<p>medicin mod diarré - Xermelo og disse lægemidler nedsætter tarmbevægelserne (antal 
afføringer), og sammen kan de forårsage alvorlig forstoppelse. Din læge kan være nødt til at 
ændre dosis af din medicin. </p>
</li>
<li>
<p>medicin til behandling af epilepsi, såsom valproat. </p>
</li>
<li>
<p>medicin til behandling af neuroendokrin tumor, såsom sunitinib eller everolimus. </p>
</li>
<li>
<p>medicin til behandling af depression, såsom bupropion eller sertralin. </p>
</li>
<li>
<p>medicin, der bruges for at undgå transplantatafstødning, såsom cyclosporin. </p>
</li>
<li>
<p>lægemidler, der sænker kolesteroltallet, såsom simvastatin. </p>
</li>
<li>
<p>oralt præventionsmiddel, såsom ethinylestradiol. </p>
</li>
<li>
<p>medicin til behandling af forhøjet blodtryk, såsom amlodipin. </p>
</li>
<li>
<p>medicin til behandling af nogle typer kræft, såsom irinotecan, capecitabin og flutamid. </p>
</li>
<li>
<p>medicin til nedsættelse af risikoen for dannelse af blodpropper, såsom prasugrel. </p>
</li>
<li>
<p>octreotid. Hvis du har behov for behandling med subkutane injektioner af octreotid, skal du 
have din injektion mindst 30 minutter efter du har taget Xermelo. </p>
</li>
</ul>
<p>Graviditet og amning 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge eller apotekspersonalet til råds, før du tager dette lægemiddel. 
Du må ikke tage denne medicin, hvis du er gravid eller kan blive gravid. Det vides ikke, hvordan 
telotristat kan påvirke barnet. 
Kvinder skal anvende et effektivt præventionsmiddel, mens de tager dette lægemiddel. 
Du må ikke amme, når du tager Xermelo, da lægemidlet kan passere videre til dit barn og kan skade 
dit barn. </p>
<p>Trafik- og arbejdssikkerhed 
Xermelo påvirker i mindre grad din evne til at køre bil eller bruge værktøj eller maskiner. Hvis du 
føler dig træt, bør du vente med at køre bil eller bruge værktøj eller maskiner til du har det bedre. </p>
<p>Xermelo indeholder lactose 
Xermelo indeholder lactose (en sukkerart). Kontakt lægen, før du tager denne medicin, hvis lægen har 
fortalt dig, at du ikke tåler visse sukkerarter. </p>
<p>Xermelo indeholder natrium 
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. tablet, dvs. det er i det 
væsentlige natriumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take xermelo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take xermelo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet. </p>
<p>Hvor meget skal du tage 
Den anbefalede dosis er 1 tablet (250 mg) 3 gange dagligt. Den maksimale dosis af Xermelo er 
750 mg pr. døgn. 
Lægen vil bestemme, hvor længe du skal tage Xermelo. 
Hvis du har leverproblemer, kan lægen beslutte at nedsætte din daglige dosis af Xermelo. </p>
<p>Sådan tager du lægemidlet </p>
<ul>
<li>
<p>Tag altid lægemidlet sammen med et måltid eller noget mad. </p>
</li>
<li>
<p>Du skal fortsat have injektioner med somatostatinanaloger (lanreotid eller octreotid), når du 
tager Xermelo.  </p>
</li>
</ul>
<p>Hvis du har taget for meget Xermelo 
Du kan få kvalme eller kaste op, få diarré eller mavesmerter. Tal med lægen. Tag 
lægemiddelpakningen med dig.  </p>
<p>Hvis du har glemt at tage Xermelo 
Hvis du glemmer at tage en dosis, så tag den næste dosis som planlagt og hop den manglende dosis 
over. Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. </p>
<p>Hvis du holder op med at tage Xermelo 
Du må ikke stoppe med at tage Xermelo uden aftale med lægen.  </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om.  </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Fortæl det straks til lægen, hvis du bemærker en af følgende bivirkninger: </p>
<ul>
<li>kvalme eller opkastning, unormalt mørk urin, gul hud eller gule øjne, smerte øverst til højre i 
maven. Dette kan være tegn på, at din lever ikke fungerer godt. Dette kan også vise sig ved 
ændringer i blodprøver som en stigning i leverenzymer: gamma-glutamyltransferase (meget 
almindelig, kan forekomme hos mere end 1 ud af 10 personer), transaminaser og alkalisk 
phosphatase i blodet (almindelig, kan forekomme hos op til 1 ud af 10 personer). </li>
</ul>
<p>Andre bivirkninger 
Fortæl lægen eller apotekspersonalet, hvis du oplever en af følgende bivirkninger: </p>
<p>Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 personer):  </p>
<ul>
<li>
<p>Mavesmerter </p>
</li>
<li>
<p>Træthed eller svaghed </p>
</li>
<li>
<p>Kvalme </p>
</li>
</ul>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 personer):  </p>
<ul>
<li>
<p>Luft i maven </p>
</li>
<li>
<p>Feber </p>
</li>
<li>
<p>Hovedpine </p>
</li>
<li>
<p>Forstoppelse </p>
</li>
<li>
<p>Oppustet mave </p>
</li>
<li>
<p>Nedsat appetit </p>
</li>
<li>
<p>Hævelse (ophobning af væske i kroppen) </p>
</li>
<li>
<p>Depression; du kan få nedsat selvværd, mangle motivation, blive trist eller i dårligt humør </p>
</li>
</ul>
<p>Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 personer): </p>
<ul>
<li>Påvirket afføring (tilstoppet tarm, fækalom). Du kan opleve forstoppelse, vandig diarré, bleg 
hud (anæmi), kvalme, opkastning, vægttab, rygsmerter eller mavesmerter, især efter at have 
spist, eller problemer med at lade vandet (vandladning). </li>
</ul>
<p>Fortæl det straks til lægen, hvis du oplever en af følgende bivirkninger: </p>
<ul>
<li>Åndedrætsbesvær, hurtigt hjerteslag, feber, inkontinens (ukontrollerbar vandladning), 
forvirring, svimmelhed eller rastløs uro. </li>
</ul>
<p>Fortæl lægen eller apotekspersonalet, hvis du oplever nogen af bivirkningerne anført herover. </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejersken. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. 
Du eller dine pårørende kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det 
nationale rapporteringssystem anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe 
med at fremskaffe mere information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store xermelo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store xermelo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Tag ikke lægemidlet efter den udløbsdato, der står på pakningen og blister efter Exp. Udløbsdatoen er 
den sidste dag i den nævnte måned. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>
<p>Dette lægemiddel kræver ingen særlige opbevaringsbetingelser. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Xermelo indeholder 
- Aktivt stof: telotristatethyl. Hver filmovertrukken tablet indeholder telotristat etiprat svarende til 
250 mg telotristatethyl. 
- Øvrige indholdsstoffer:<br />
Tabletkerne: lactose (se pkt. 2 under "Xermelo indeholder lactose"), hydroxypropylcellulose, 
croscarmellosenatrium, magnesiumstearat og kolloid vandfri silica,  </p>
<p>Filmovertræk: poly(vinylalkohol) (E1203), titandioxid (E171), macrogol 3350 (E1521) og 
talcum (E553b). </p>
<p>Udseende og pakningsstørrelser 
Tabletterne er hvide til råhvide, filmovertrukne og har oval form. Hver tablet er cirka 17 mm lang og 
7,5 mm bred og med "T-E" præget på den ene side og "250" præget på den anden side. Tabletterne er 
pakket i et PVC/PCTFE/PVC/Alu-blisterkort. Blisterkortene er pakket i papæske. </p>
<p>Pakninger a 90 og 180 tabletter. Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller </p>
<p>Indehaver af markedsføringstilladelsen 
SERB SAS<br />
40 Avenue George V<br />
75008 Paris <br />
Frankrig </p>
<p>Fremstiller 
Tjoapack Netherlands B.V. 
Nieuwe Donk 9 
4879 AC Etten-Leur<br />
Holland </p>
<p>Denne indlægsseddel blev senest ændret </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. Der er også links til andre websteder om sjældne sygdomme 
og om, hvordan de behandles. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-a7d93b3af6f699fe631629c6d79268c4
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for xermelo Package Leaflet for language en"
Description: "ePI document Bundle for xermelo Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-a7d93b3af6f699fe631629c6d79268c4"
* entry[0].resource = composition-en-a7d93b3af6f699fe631629c6d79268c4

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpa7d93b3af6f699fe631629c6d79268c4"
* entry[=].resource = mpa7d93b3af6f699fe631629c6d79268c4
                            
                    
Instance: bundlepackageleaflet-da-a7d93b3af6f699fe631629c6d79268c4
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for xermelo Package Leaflet for language da"
Description: "ePI document Bundle for xermelo Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-a7d93b3af6f699fe631629c6d79268c4"
* entry[0].resource = composition-da-a7d93b3af6f699fe631629c6d79268c4

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpa7d93b3af6f699fe631629c6d79268c4"
* entry[=].resource = mpa7d93b3af6f699fe631629c6d79268c4
                            
                    



Instance: mpa7d93b3af6f699fe631629c6d79268c4
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Xermelo 250 mg film-coated tablets"
Description: "Xermelo 250 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/17/1224/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Xermelo 250 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: a7d93b3af6f699fe631629c6d79268c4ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "xermelo"

* status = #current
* mode = #working

* title = "List of all ePIs associated with xermelo"

* subject = Reference(mpa7d93b3af6f699fe631629c6d79268c4)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#xermelo "xermelo"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-a7d93b3af6f699fe631629c6d79268c4) // xermelo en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-a7d93b3af6f699fe631629c6d79268c4) // xermelo da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-a7d93b3af6f699fe631629c6d79268c4
InstanceOf: List

* insert a7d93b3af6f699fe631629c6d79268c4ListRuleset
    